Patent · US Active

Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine

US10934317B2 · kind B2 · utility

0Cited by

4References

13Claims

0Family size

Assignee

Ariad Pharmaceuticals, Inc. · US

Inventors

Leonard W. Rozamus · Andover, US
Pradeep Sharma · Westford, US

Key dates

Filing date	Jun 3, 2019
Grant date	Mar 2, 2021
Priority date	—
Expiry date	Jun 3, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.